POLYCYTHEMIA VERA

This study tests an experimental drug called IMG-7289 in people with two rare blood cancers—essential thrombocythemia (ET) and polycythemia vera (PV)—whose disease did not get better with or could not tolerate standard treatments. The goal is to see if the drug can help control b…

This study tests a new drug called SLN124 in adults with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to see if SLN124 is safe and can reduce the need for phlebotomies (removing blood). The trial has two parts: first, an open-label pha…

This study is testing a combination of three drugs (azacitidine, venetoclax, and pevonedistat) in adults with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that is related to prior cancer treatment or other blood disorders. The goal is to find the best dose a…

This program gives eligible patients with polycythemia vera (a rare blood cancer causing too many red blood cells) access to the drug ruxolitinib. It is for people aged 12 and older who cannot take or have stopped responding to standard treatments like hydroxyurea. The goal is to…

This study follows 319 adults with polycythemia vera (a rare blood cancer) who are taking ropeginterferon alfa-2b as part of their normal care. Researchers want to see how many people can take the drug without major side effects and how well it controls their blood counts. The go…

This study looks at the long-term safety of the drugs ruxolitinib (alone or with panobinostat) in people with certain blood diseases like myelofibrosis, polycythemia vera, graft-versus-host disease, acute myeloid leukemia, or thalassemia. Participants had already been taking thes…

This study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…

This study tests whether adding the experimental drug veliparib to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. About 25 adults took part. The goal was to see…

This study watches 242 people with high-risk polycythemia vera, a blood condition that raises the risk of dangerous blood clots. Researchers track things like blood pressure, weight, and lab tests to see which factors best predict clots. The goal is to help doctors identify who i…